United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma

被引：1

作者：

Tarantelli, Chiara ^{[1
]}

Bertoni, Francesco ^{[1
,2
]}

机构：

[1] Fac Biomed Sci, Inst Oncol Res, Via Francesco Chiesa 5, CH-6500 Bellinzona, Switzerland

[2] Ente Osped Cantonale, Dept Oncol, Oncol Inst Southern Switzerland, Bellinzona, Switzerland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 02期

关键词：

antibody-drug conjugate; lymphoma; MMAE; polatuzumab vedotin; resistance; rituximab;

D O I：

10.1111/bjh.18384

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC. Commentary on: Kawasaki et al. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. Br J Haematol 2022 (Online ahead of print). doi: 10.1111/bjh.18341.

引用

页码：169 / 170

页数：2

共 10 条

[1] Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma [J].

Dang, Nam H. ;

Ogura, Michinori ;

Castaigne, Sylvie ;

Fayad, Luis E. ;

Jerkeman, Mats ;

Radford, John ;

Pezzutto, Antonio ;

Bondarenko, Igor ;

Stewart, Douglas A. ;

Shnaidman, Michael ;

Sullivan, Sharon ;

Vandendries, Erik ;

Tobinai, Kensei ;

Ramchandren, Radhakrishnan ;

Hamlin, Paul A. ;

Gine, Eva ;

Ando, Kiyoshi .

BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (04) :583-586

[2] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma [J].

Dornan, David ;

Bennett, Fiona ;

Chen, Yvonne ;

Dennis, Mark ;

Eaton, Dan ;

Elkins, Kristi ;

French, Dorothy ;

Go, Mary Ann T. ;

Jack, Andrew ;

Junutula, Jagath R. ;

Koeppen, Hartmut ;

Lau, Jeffrey ;

McBride, Jacqueline ;

Rawstron, Andy ;

Shi, Xiaoyan ;

Yu, Nancy ;

Yu, Shang-Fan ;

Yue, Peng ;

Zheng, Bing ;

Ebens, Allen ;

Polson, Andrew G. .

BLOOD, 2009, 114 (13) :2721-2729

[3] Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models [J].

Gaudio, Eugenio ;

Tarantelli, Chiara ;

Spriano, Filippo ;

Guidetti, Francesca ;

Sartori, Giulio ;

Bordone, Roberta ;

Arribas, Alberto J. ;

Cascione, Luciano ;

Bigioni, Mario ;

Merlino, Giuseppe ;

Fiascarelli, Alessio ;

Bressan, Alessandro ;

Mensah, Afua Adjeiwaa ;

Golino, Gaetanina ;

Lucchini, Renzo ;

Bernasconi, Elena ;

Rossi, Davide ;

Zucca, Emanuele ;

Stussi, Georg ;

Stathis, Anastasios ;

Boyd, Robert S. ;

Dusek, Rachel L. ;

Bisht, Arnima ;

Attanasio, Nickolas ;

Rohlff, Christian ;

Pellacani, Andrea ;

Binaschi, Monica ;

Bertoni, Francesco .

HAEMATOLOGICA, 2020, 105 (11) :2584-2591

[4] Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study [J].

Gritti, Giuseppe ;

Marlton, Paula ;

Phillips, Tycel J. ;

Arthur, Christopher ;

Bannerji, Rajat ;

Corradini, Paolo ;

Johnston, Anna ;

Seymour, John F. ;

Yuen, Sam ;

Hirata, Jamie ;

Musick, Lisa ;

Saha, Sourish ;

Croft, Brandon ;

Flowers, Christopher .

BLOOD, 2020, 136

[5] The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma [J].

Kawasaki, Natsumi ;

Nishito, Yukari ;

Yoshimura, Yasushi ;

Yoshiura, Shigeki .

BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) :245-255

[6]

Levy M.Y., 2021, Blood, V138, P526, DOI [10.1182/blood-2021-145102, DOI 10.1182/BLOOD-2021-145102]

[7] Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma [J].

Linhares, Yuliya ;

Gandhi, Mitul D. ;

Chung, Michael ;

Adeleye, Jennifer ;

Ungar, David ;

Hamadani, Mehdi .

BLOOD, 2020, 136

[8] Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) [J].

Morschhauser, Franck ;

Flinn, Ian W. ;

Advani, Ranjana ;

Sehn, Laurie H. ;

Diefenbach, Catherine ;

Kolibaba, Kathryn ;

Press, Oliver W. ;

Salles, Gilles ;

Tilly, Herve ;

Chen, Andy I. ;

Assouline, Sarit ;

Cheson, Bruce D. ;

Dreyling, Martin ;

Hagenbeek, Anton ;

Zinzani, Pier Luigi ;

Jones, Surai ;

Cheng, Ji ;

Lu, Dan ;

Penuel, Elicia ;

Hirata, Jamie ;

Wenger, Michael ;

Chu, Yu-Waye ;

Sharman, Jeff .

LANCET HAEMATOLOGY, 2019, 6 (05) :E254-E265

[9] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: survival update and new extension cohort data [J].

Sehn, Laurie H. ;

Hertzberg, Mark ;

Opat, Stephen ;

Herrera, Alex F. ;

Assouline, Sarit ;

Flowers, Christopher R. ;

Kim, Tae Min ;

McMillan, Andrew ;

Ozcan, Muhit ;

Safar, Violaine ;

Salles, Gilles ;

Ku, Grace ;

Hirata, Jamie ;

Chang, Yi Meng ;

Musick, Lisa ;

Matasar, Matthew J. .

BLOOD ADVANCES, 2022, 6 (02) :533-543

[10] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma [J].

Tilly, Herve ;

Morschhauser, Franck ;

Sehn, Laurie H. ;

Friedberg, Jonathan W. ;

Trneny, M. ;

Sharman, Jeff P. ;

Herbaux, Charles ;

Burke, John M. ;

Matasar, Matthew ;

Rai, Shinya ;

Izutsu, Koji ;

Mehta-Shah, Neha ;

Oberic, Lucie ;

Chauchet, Adrien ;

Jurczak, Wojciech ;

Song, Yuqin ;

Greil, Richard ;

Mykhalska, Larysa ;

Bergua-Burgues, Juan M. ;

Cheung, Matthew C. ;

Pinto, Antonio ;

Shin, Ho-Jin ;

Hapgood, Greg ;

Munhoz, Eduardo ;

Abrisqueta, Pau ;

Gau, Jyh-Pyng ;

Hirata, Jamie ;

Jiang, Yanwen ;

Yan, Mark ;

Lee, Calvin ;

Flowers, Christopher R. ;

Salles, Gilles .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) :351-363

← 1 →